TEAM SCIENCE AT A PROGRAMMATIC LEVEL. Sundeep Khosla, M.D. Mayo Clinic College of Medicine
|
|
- Lynette Griffin
- 5 years ago
- Views:
Transcription
1 TEAM SCIENCE AT A PROGRAMMATIC LEVEL Sundeep Khosla, M.D. Mayo Clinic College of Medicine
2 APPROACH TO TRANSLATIONAL RESEARCH IN OSTEOPOROSIS Epidemiological Studies Clinical Investigation Mouse and Cellular Models Translation into Practice
3 FRACTURES IN MEN Incidence/1, person-yr Hip Vertebrae Colles Men Women Age group, yr Cooper & Melton, Trends Endocrinol Metab 8:225, 1992
4 LIFETIME RISK OF FRACTURE AT AGE 5 YEARS (%) White women White men Hip fracture Vertebral fractue Forearm fracture Any of the Annual healthcare costs ~ $17B Cummings & Melton, Lancet 359:1761, 22
5 ESTROGEN VERSUS ANDROGEN EFFECTS ON THE SKELETON TRADITIONAL VIEW Oophorectomy/menopause in women loss of E BR/ BF Rapid bone loss Therefore, E regulates bone metabolism in women
6 EFFECT OF ORCHIDECTOMY ON BMD IN MEN 1.4 BMD, gm/cm Stepan et al. JCEM 69:523, Time after Orchidectomy, yrs
7 ESTROGEN VERSUS ANDROGEN EFFECTS ON THE SKELETON TRADITIONAL VIEW Oophorectomy/menopause in women loss of E BR/ BF Rapid bone loss Therefore, E regulates bone metabolism in women Orchidectomy in men loss of T BR/ BF Rapid bone loss Therefore, T regulates bone metabolism in men
8 ROLE OF ESTROGEN IN THE MALE SKELETON Evidence from experiments of nature An estrogen receptor (ER) mutant male (Smith et al. NEJM 331:156, 1994) and two aromatase deficient males (Morishima et al. JCEM 8:3689, 1995; Carani Et al. NEJM 337:91, 1997) were described All three individuals had unfused epiphyses, high rates of bone resorption (and formation), and osteopenia
9 INSIGHTS FROM THE ERα AND AROMATASE DEFICIENT MALES E is required for epiphyseal closure Presence of E is necessary for the acquisition of bone mass during puberty in boys
10 ISSUES LEFT UNRESOLVED BY THE ERα AND AROMATASE DEFICIENT MALES What if any, is the role of E in regulating bone remodeling in adult men with mature skeletons? What is the role of E or T deficiency in mediating age-related bone loss in men
11 APPROACH TO TRANSLATIONAL RESEARCH IN OSTEOPOROSIS Epidemiological Studies Clinical Investigation Mouse and Cellular Models Translation into Practice
12 DISSECTING RELATIVE CONTRIBUTIONS OF E VS T TO BONE TURNOVER IN MEN Visit Entry Baseline Final Weeks Leuprolide Leuprolide Letrozole T + E Patch Falahati-Nini et al. JCI 16: , 2 A: No Patch B: E Patch C: T Patch D: T + E Patch T Patch
13 IN VIVO EFFECTS OF SEX STEROIDS ON BONE RESORPTION MARKERS 4 3 ** *** *** P <.1 ** P <.5 * P <.5 Dpd % change 2 1 NTx -1 Group A Group B (-T, -E) (-T, +E) Group C (+T, -E) Group D (+T, +E)
14 IN VIVO EFFECTS OF SEX STEROIDS ON BONE RESORPTION MARKERS 4 3 ** *** *** P <.1 ** P <.5 * P <.5 Dpd % change 2 1 * NTx -1 Group A Group B (-T, -E) (-T, +E) Group C (+T, -E) Group D (+T, +E)
15 IN VIVO EFFECTS OF SEX STEROIDS ON BONE RESORPTION MARKERS % change ** *** * * ** *** P <.1 ** P <.5 * P <.5 Dpd ANOVA E effect: P =.5 T effect: P =.232 NTx -1 Group A Group B (-T, -E) (-T, +E) Group C (+T, -E) Group D (+T, +E) ANOVA E effect: P =.2 T effect: P =.85
16 IN VIVO EFFECTS OF SEX STEROIDS ON SERUM OSTEOCALCIN LEVELS Serum Osteocalcin, % change *** *** P <.1 Group A (-T, -E) Group B (-T, +E) Group C (+T, -E) Group D (+T, +E)
17 IN VIVO EFFECTS OF SEX STEROIDS ON SERUM OSTEOCALCIN LEVELS Serum Osteocalcin, % change *** *** P <.1 Group A (-T, -E) Group B (-T, +E) Group C (+T, -E) Group D (+T, +E)
18 IN VIVO EFFECTS OF SEX STEROIDS ON SERUM OSTEOCALCIN LEVELS Serum Osteocalcin, % change ANOVA *** E effect: P =.2; T effect: P =.13 *** P <.1 Group A (-T, -E) Group B (-T, +E) Group C (+T, -E) Group D (+T, +E)
19 E VS T EFFECTS ON BONE TURNOVER IN MEN: SUMMARY In men, E is the dominant sex steroid regulating bone resorption, although T (in the absence of aromatization to E) may make a smaller contribution (< 3%) Both E and T contribute to the maintenance of bone formation
20 E DEFICIENCY IS THE PRIMARY MEDIATOR OF BONE LOSS IN HYPOGONADAL MEN Healthy men (age 2-5 yrs) given GnRH and aromatase blocker for 16 weeks Treated with 5 doses of T (, 1.25 g, 2.5 g, 5 g, 1 g) All subjects had suppressed E 2 levels ( pg/ml) T levels: 43, 234, 378, 497, and 985 ng/dl Regardless of the T level, in the setting of low E 2 levels, bone loss (total, cortical, trabecular density, cortical area and thickness) was identical in all the T groups Yu et al. ASBMR, 212 (#1199)
21 RALOXIFENE IN MEN Study Design 5 elderly men, mean age 69 years Randomized to placebo or raloxifene, 6 mg/d, for 6 months Baseline and 6 month assessment of bone turnover markers Doran et al. JBMR 16: , 21
22 RALOXIFENE IN MEN Changes in PTH and bone turnover markers Placebo Raloxifene P-value PTH, pmol/l +.2 ± ± BSAP, U/L -1 ± 1 ±.1 Urine NTx, nmol/d -17 ± 12 3 ± 11.19
23 RALOXIFENE IN MEN Change in Urine NTx Excretion as a Function of Baseline E 2 Levels Urinary NTx Excretion, nmol /24 hr Raloxifene R =.57 P < Baseline Serum Estradiol, pg/ml Placebo R = -.15 P = Baseline Serum Estradiol, pg/ml
24 RALOXIFENE IN MEN Change in Urine NTx Excretion as a Function of Baseline E 2 Levels Urinary NTx Excretion, nmol /24 hr Raloxifene R =.57 P <.1 26 pg/ml Baseline Serum Estradiol, pg/ml Placebo R = -.15 P = Baseline Serum Estradiol, pg/ml
25 APPROACH TO TRANSLATIONAL RESEARCH IN OSTEOPOROSIS Epidemiological Studies Clinical Investigation Mouse and Cellular Models Translation into Practice
26 RELATIONSHIP OF E 2 VS. T LEVELS TO FRACTURE RISK IN OLDER MEN Serum sex steroids analyzed by GC-MS at baseline in older men (n = 2639, mean age 75 years) Fractures occurring after baseline were validated (average follow up of 3.3 years) Mellström et al. JBMR 23:1552, 28
27 RELATIONSHIP OF E 2 VS. T LEVELS TO FRACTURE RISK IN OLDER MEN (Cont d) Age-adjusted HR for risk of first fracture Low E 2 : 16 pg/ml Low T: 336 ng/dl (Lowest quartiles for each) I: nl E 2, nl T II: low E 2, nl T III: nl E 2, low T IV: low E 2, low T
28 RELATIONSHIP OF E 2 VS. T LEVELS TO FRACTURE RISK IN OLDER MEN (Cont d) Poisson regression model 12 Incidence/1 person-years E2, pg/ml
29 BIOAVAILABLE VS SHBG-BOUND SEX STEROIDS NON-BIOAVAILABLE BIOAVAILABLE T T E 2 E 1 Free (1-3%) ~5% SHBG (~9 kd) E 2 E T 2 E 1 E 1 ALBUMIN (~66 kd) ~5%
30 SERUM TOTAL TESTOSTERONE AND ESTRADIOL LEVELS AS A FUNCTION OF AGE IN ROCHESTER, MN MEN AND WOMEN Total T, ng/dl Total E 2, pg/ml Pre Post Pre Post Age, yrs Age, yrs Khosla et al. JCEM 83:2266, 1998
31 SERUM BIOAVAILABLE TESTOSTERONE AND ESTRADIOL LEVELS AS A FUNCTION OF AGE IN ROCHESTER, MN MEN AND WOMEN 2 3 Bioavailable T, ng/dl Bioavailable E 2, pg/ml Pre Post Pre Post Age, yrs Age, yrs Khosla et al. JCEM 83:2266, 1998
32 CHANGES IN SERUM SHBG IN MEN 6 SHBG, nmol/l 4 2 < Age, yrs Khosla et al. JCEM 83:2266,
33 SUMMARY: AGE-RELATED CHANGES IN SEX STEROIDS Abrupt decrease in total and bioavailable estrogen levels in women at the time of menopause More gradual decreases in serum bioavailable testosterone and estrogen levels in men starting at age 5-6 years Marked increase in men in serum SHBG levels starting at age 5-6 years
34 APPROACH TO TRANSLATIONAL RESEARCH IN OSTEOPOROSIS Epidemiological Studies Clinical Investigation Mouse and Cellular Models Translation into Practice
35 IN VIVO EFFECTS OF SEX STEROIDS ON BONE RESORPTION MARKERS % change ** *** * * ** *** P <.1 ** P <.5 * P <.5 Dpd NTx -1 Group A Group B (-T, -E) (-T, +E) Group C (+T, -E) Group D (+T, +E)
36 IN VIVO EFFECTS OF SEX STEROIDS ON SERUM OSTEOCALCIN LEVELS Serum Osteocalcin, % change *** *** P <.1 Group A (-T, -E) Group B (-T, +E) Group C (+T, -E) Group D (+T, +E)
37 DIFFERENTIAL EFFECTS OF E AND T ON BONE RESORPTION MARKERS IN YOUNG MEN Percent Change Percent Change Urinary Deoxypyridinoline Serum Osteocalcin Serum N-telopeptide Time after GnRH, weeks Time after GnRH, weeks Leder et al. JCEM 88: 24, 23 Percent Change Percent Change Serum PINP
38 DIFFERENTIAL EFFECTS OF E AND T ON BONE RESORPTION MARKERS IN YOUNG MEN Percent Change Percent Change Leder et al. JCEM 88: 24, Urinary Deoxypyridinoline Phase I. Uncoupling Serum Osteocalcin Percent Change Percent Change -1 Serum N-telopeptide Serum PINP Time after GnRH, weeks Time after GnRH, weeks Phase I. Uncoupling
39 DIFFERENTIAL EFFECTS OF E AND T ON BONE RESORPTION MARKERS IN YOUNG MEN Percent Change Percent Change Leder et al. JCEM 88: 24, Urinary Deoxypyridinoline Phase II. Re-coupling Serum Osteocalcin Percent Change Percent Change -1 Serum N-telopeptide Serum PINP Time after GnRH, weeks Time after GnRH, weeks Phase II. Re-coupling
40 ACUTE CHANGES IN BONE FORMATION AND OC # s FOLLOWING OVX IN RATS BFR/BS, µm 3 /µm 2 per day (X1-2 ) Sham OVX ** *P<.2, **P<.2 vs Sham Pre Days following OVX * OCs/BS (%) *P<.5 SHAM * OVX Lean et al. J Endocrinol 142:119, 1994
41 OSTEOCLAST OSTEOBLAST REGULATION OF OSTEOBLAST OSTEOCLAST FORMATION/FUNCTION Stimulatory Factors Inhibitory Factors OC PRECURSORS Differentiation and activation ACTIVE OC OC APOPTOSIS OPG IL-6 IL-7 PGE 2 GM-CSF M-CSF RANKL RANKL Osteoclast-derived TGFβ coupling factors TGFβ OSTEOPROGENITOR/ OSTEOBLASTS
42 BONE MARROW-BONE INTERFACE
43 BONE REMODELING COMPARTMENT Hauge et al. JBMR 16:1575, 21
44 SCHEMATIC OF THE BONE REMODELING COMPARTMENT Khosla, Westendorf, Oursler JCI 118:421, 28
45 POTENTIAL MECHANISMS FOR COUPLING BONE FORMATION TO BONE RESORPTION Cell-cell contact Factors released from the bone matrix Osteoclast-derived secreted factors
46 BIDIRECTIONAL EPHRIN SIGNALING BETWEEN OSTEOCLASTS AND OSTEOBLASTS Mundy & Elefteriou Cell 126:441, 26; Zhao et al. Cell Metab 4:111, 26
47 ROLE OF TGFβ1 IN COUPLING BONE RESORPTION TO BONE FORMATION Iqbal & Zaidi Nat Med 15:729, 29; Tang et al. Nat Med 15:757, 29
48 SCHEMATIC OF THE BONE REMODELING COMPARTMENT
49 OSTEOCLAST CONDITIONED MEDIA STIMULATES MINERALIZATION ALIZARIN RED Osteoclast Precursor CM Mature Osteoclast CM Alizarin red units OC Precursor Conditioned Media Mature OC Conditioned Media * Pederson et al. PNAS 15:2764, 28
50 MARROW-DERIVED OSTEOCLAST COUPLING FACTOR EXPRESSION Pederson et al. PNAS 15:2764, 28
51 COUPLING FACTOR HYPOTHESIS BMP6 Wnts S1P SCLEROSTIN
52 APPROACH TO TRANSLATIONAL RESEARCH IN OSTEOPOROSIS Epidemiological Studies Clinical Investigation Mouse and Cellular Models Translation into Practice
53 CLINICAL IMPLICATIONS Use of serum estradiol levels in the evaluation of male osteoporosis
54 POTENTIAL CLINICAL APPROACH Male with low T (< 3 ng/ml), osteoporosis/increased fracture risk E 2 normal (> 16 pg/ml by mass spec): standard pharmacological therapy (e.g., bisphosphonate) E 2 low (< 16 pg/ml): Consider trial of T therapy and monitor BMD
55 CHANGES IN SERUM E 2 FOLLOWING TRANSDERMAL T REPLACEMENT 5 E 2, pg/ml Months Wang et al. JCEM 89:285, 24
56 CLINICAL IMPLICATIONS Use of serum estradiol levels in the evaluation of male osteoporosis Use of selective estrogen receptor modulators in male osteoporosis
57 RALOXIFENE IN MEN WITH PROSTATE CANCER ON GnRH Smith et al. JCEM 89:3841, 24 Percent change Lumbar spine P=.7 Percent change Total hip P<.1 Raloxifene n = 19 Percent change Trochanter P< Month Percent change Femoral neck P= Month No raloxifene n =22
58 EFFECTS OF THE SERM, TOREMIFINE, ON VERTEBRAL FRACTURES IN MEN WITH PROSTATE CANCER 1284 men with prostate cancer on ADT randomized to receive 8 mg toremifine or placebo for up to 24 months 5% reduction noted in vertebral fractures in the toremifene treated group (P =.5) Smith et al. J Urol 184:1316, 21
59 CLINICAL IMPLICATIONS Use of serum estradiol levels in the evaluation of male osteoporosis Use of selective estrogen receptor modulators in male osteoporosis Cautionary note regarding possible efficacy of nonaromatizable selective androgen receptor modulators in preventing bone loss in men
60 CLINICAL IMPLICATIONS Use of serum estradiol levels in the evaluation of male osteoporosis Use of selective estrogen receptor modulators in male osteoporosis Cautionary note regarding possible efficacy of nonaromatizable selective androgen receptor modulators in preventing bone loss in men Based on osteoclast-derived osteoblast coupling factors, potential development of novel bone formation-stimulating agents
61 ACKNOWLEDGEMENTS B. Lawrence Riggs L. Joseph Melton III Shreyasee Amin Merry Jo Oursler Jennifer Westendorf Matthew Drake David Monroe Terry Therneau Elizabeth Atkinson Sara Achenbach Richard Robb/Jon Camp Louise McCready Amanda Tweed Margaret Holets Kelley Hoey Jim Peterson Dan Fraser Matt Roforth Ulrike Mödder Farhan Syed Patrick Doran Ali-Falahati Nini Kristy Nicks K. Chokalingam
62 RESEARCH SUPPORT MAYO CTSA MAYO FOUNDATION
Osteoporosis in Men Professor Peter R Ebeling
Osteoporosis in Men MD FRACP Head, Department of Medicine, School for Clinical Sciences Monash Health Translation Precinct Monash University, Clayton, Victoria 1 MonashHealth Potential Conflicts Departmental
More informationNEW HORIZONS IN OSTEOPOROSIS THERAPY. Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN
NEW HORIZONS IN OSTEOPOROSIS THERAPY Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN DISCLOSURES SUNDEEP KHOSLA, M.D. Investigator-initiated grant Merck No non-fda approved recommendations RISK ASSESSMENT
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationPathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis. March 15, 2016 Bone ECHO Kate T Queen, MD
Pathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis March 15, 2016 Bone ECHO Kate T Queen, MD Review: normal bone formation Bone Modeling Remodeling Peak Bone Mass Maximum bone mass
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationBreast Cancer and Bone Health. Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield
Breast Cancer and Bone Health Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield Breast Cancer and Bone Health Normal Bone Health Impact of Cancer Therapies on Bone Health Therapeutic
More informationTHE GROWING GAP IN OSTEOPOROSIS TREATMENT
THE GROWING GAP IN OSTEOPOROSIS TREATMENT Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN DISCLOSURES SUNDEEP KHOSLA, M.D. NONE 1 OVERALL CONCLUSIONS There has been remarkable progress in our understanding
More informationOsteoporosis - Pathophysiology and diagnosis. Bente L Langdahl Department of Endocrinology Aarhus University Hospital Aarhus, Denmark
Osteoporosis - Pathophysiology and diagnosis Bente L Langdahl Department of Endocrinology Aarhus University Hospital Aarhus, Denmark Objective General knowledge about osteoporosis Optimise your protocols
More informationHRT and Risedronate Combined Anabolic and Antiresorptive Therapy
Optimizing Combined and Sequential Osteoanabolic and Antiresorptive Therapy Benjamin Leder, M.D. Endocrine Unit Massachusetts General Hospital Boston, MA Antiresorptive and Osteoanabolic Therapies Increase
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationNew Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence
New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence John P. Bilezikian, MD, PhD(hon), MACE Silberberg Professor of Medicine Vice-Chair for International
More informationThis is a free sample of content from Bone: A Regulator of Physiology. Click here for more information on how to buy the book.
Regulation of Bone Metabolism by Sex Steroids Sundeep Khosla and David G. Monroe Robert and Arlene Kogod Center on Aging and Endocrine Research Unit, Mayo Clinic College of Medicine, Rochester, Minnesota
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationA KL/R / AN A K/O / P O G G
Outline and New Treatments on the Horizon Steven R. Cummings, MD CPMC and UCSF San Francisco Coordinating Center Support from Lilly and Amgen New treatments, new mechanisms of action Cathepsin K inhibition
More information7/5/2016. We need drugs that. Disclosures. New Osteoporosis Treatments. What we have today. Maintain or promote bone formation
New Osteoporosis Treatments Disclosures Mary L. Bouxsein, PhD Department of Orthopedic Surgery Harvard Medical School, Boston, MA Advisory Board: Research funding: Merck, Eli Lilly, Radius Merck, Amgen
More informationToremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Matthew R. Smith,*,, Ronald A. Morton,* K. Gary Barnette,* Paul R. Sieber, S. Bruce Malkowicz, Domingo
More informationHormones Impact on Bone Health Throughout the Lifespan. Outline. Sex differences in: Osteoporosis and fracture rates. Secondary causes of osteoporosis
Hormones Impact on Bone Health Throughout the Lifespan Meryl S. LeBoff, MD Director, Skeletal Health and Osteoporosis Chief, Calcium and Bone Section Brigham and Women s Hospital Professor of Medicine,
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationUpdate on diagnosis and complications of adult and elderly male hypogonadism
Hypoandrogenism in the elderly: to treat or not to treat? 12 th Italian AME Meeting; 6 th joint Meeting with AAC Bari november 10th Update on diagnosis and complications of adult and elderly male hypogonadism
More informationEffects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis
Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis Mohamed Yassin 1 Ashraf T. Soliman2, Mohamed O. Abdelrahman3, Vincenzo De Sanctis 4 Departments of, 1 Hematology 2Pediatric
More informationAlendronate sodium in the management of osteoporosis
REVIEW Alendronate sodium in the management of osteoporosis P J J Prinsloo 1 D J Hosking 2 1 Dept of Clinical Chemistry, City Hospital, Nottingham, UK; 2 Dept Endocrinology and Diabetes, City Hospital,
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Osteoporosis in Men: An Update on the Epidemiology, Clinical Evaluation Current Treatments and Treatments in Development Learning
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationBest Practice & Research Clinical Endocrinology & Metabolism
Best Practice & Research Clinical Endocrinology & Metabolism 25 (2011) 321 335 Contents lists available at ScienceDirect Best Practice & Research Clinical Endocrinology & Metabolism journal homepage: www.elsevier.com/locate/beem
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationReview Article RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
SAGE-Hindawi Access to Research Osteoporosis Volume 2011, Article ID 941310, 6 pages doi:10.4061/2011/941310 Review Article RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
More informationResearch Article Testosterone and the Male Skeleton: A Dual Mode of Action
SAGE-Hindawi Access to Research Osteoporosis Volume 2011, Article ID 240328, 7 pages doi:10.4061/2011/240328 Research Article Testosterone and the Male Skeleton: A Dual Mode of Action Mieke Sinnesael,
More informationClinical Study Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog
Hindawi Publishing Corporation Prostate Cancer Volume 2, Article ID 7664, 7 pages doi:.55/2/7664 Clinical Study Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationReview Article Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis
International Journal of Endocrinology, Article ID 235060, 25 pages http://dx.doi.org/10.1155/2014/235060 Review Article Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis Vittorio Locatelli 1 and
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationObjectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.
Objectives Discuss bone health and the consequences of osteoporosis on patients medical and disability status. Discuss the pathophysiology of osteoporosis and major risk factors. Assess the major diagnostic
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationImaging to Assess Bone Strength and its Determinants
Imaging to Assess Bone Strength and its Determinants Mary L. Bouxsein, PhD Harvard Medical School, Boston, MA UCSF Osteoporosis Course 26 July 212 Consultant / advisor: Amgen, Eli Lilly, Merck Research
More informationOSTEONECROSI DEI MASCELLARI (ONJ): PREVENZIONE, DIAGNOSI, TRATTAMENTO UPDATE 2010
OSTEONECROSI DEI MASCELLARI (ONJ): PREVENZIONE, DIAGNOSI, TRATTAMENTO UPDATE 2010 Alessandria, 5 giugno 2010 Novità nel trattamento dell osteoporosi Stefania Boldini Francesco Bertoldo Dipartimento di
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationOsteoporosis in Men Eric Orwoll Oregon Health & Science University
Osteoporosis in Men Eric Orwoll Oregon Health & Science University Ris k Factor Risk factors for hip fracture in men Multivariate HR + 95% CI Age 2.3 (1.6, 2.4) FN BMD 3.0 (2.5, 3.7) 5994 men age >65 yrs
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationInteractions between bone and the central nervous system Florent Elefteriou, PhD
Interactions between bone and the central nervous system Florent Elefteriou, PhD Department of Medicine Center for Bone Biology VANDERBILT UNIVERSITY Nashville, USA BONE REMODELING Bone marrow cells Estrogen
More informationReview Article The Endocrine Role of Estrogens on Human Male Skeleton
International Journal of Endocrinology Volume 2015, Article ID 165215, 15 pages http://dx.doi.org/10.1155/2015/165215 Review Article The Endocrine Role of Estrogens on Human Male Skeleton Vincenzo Rochira,
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationManaging the Patient with Osteoporosis Undergoing Spinal Surgery
11/4/16 DISCLOSURES Managing the Patient with Osteoporosis Undergoing Spinal Surgery MEDTRONIC LILLY MISONIX SHANE BURCH MD, MS, FRCSC Associate Professor in Residence UCSF Department of Orthopedic Surgery
More informationOsteoporosis: Not Just for Women Anymore. Osteoporosis is characterized by low bone. By Lisanne G. Laurier, MD, PhD, FRCPC.
Focus on CME at the University of Western Ontario Osteoporosis: Not Just for Women Anymore By Lisanne G. Laurier, MD, PhD, FRCPC Osteoporosis is characterized by low bone mass and microarchitectural deterioration
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationOriginal Article Fasting Plasma Glucose Levels Are Related to Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism
www.ijcem.com/ijcem807001 Original Article Fasting Plasma Glucose Levels Are Related to Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism Itoko Hisa 1, Hiroshi Kaji 1, Yoshifumi
More informationBad to the Bones: Diabetes and Thiazolidinediones 9/9/2010. Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism
Bad to the Bones: Diabetes and Thiazolidinediones 9/9/2010 Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism Any reduction of bone mass in diabetics that is revealed
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationUpcoming Agents for Osteoporosis
Upcoming Agents for Osteoporosis May 5, 2017 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Professorial Fellow, Institute of Health and Ageing Australian Catholic
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationMusculoskeletal Clinical Correlates: Osseous Conditions in Dental Patients
Musculoskeletal Clinical Correlates: Osseous Conditions in Dental Patients Learning Objectives Define osteoporosis and explain how it is diagnosed. Describe the main risk factors for developing osteoporosis.
More informationElecsys bone marker panel. Optimal patient management starts in the laboratory
bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic
More informationOsteoporosis Screening and Treatment in Type 2 Diabetes
Osteoporosis Screening and Treatment in Type 2 Diabetes Ann Schwartz, PhD! Dept. of Epidemiology and Biostatistics! University of California San Francisco! October 2011! Presenter Disclosure Information
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationOsteoporosis Medications: A Case-Based Discussion. Laila S. Tabatabai, MD August 5, 2017
Osteoporosis Medications: A Case-Based Discussion Laila S. Tabatabai, MD August 5, 2017 Disclosures Eli Lilly Radius Objectives Determine which patients with low bone density require treatment, along with
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationBecause the low bone mass and deterioration
OSTEOPOROSIS A look at recent expert guidelines and key studies in bone health, the findings of which affect your patients young and old Steven R. Goldstein, MD Dr. Goldstein is Professor of Obstetrics
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationNew treatment targets in osteoporosis
National University of Athens Greece New treatment targets in osteoporosis Gourzi Vassiliki PhD Candidate Dept. of Pathophysiology School of Medicine Bone remodeling Physiological process < bone tissue
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationNote: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables.
index Note: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables. Abaloparatide (PTHrP[1-34]), 181t, 234, 237 239. See also Parathyroid hormone (PTH). action mechanism,
More informationBIOLOGY and BIOMECHANICS OF NORMAL & OSTEOPOROTIC BONE
BIOLOGY and BIOMECHANICS OF NORMAL & OSTEOPOROTIC BONE Andreas Panagopoulos, MD, PhD Assistant Professor in Orthopaedics University Hospital of Patras, Orthopaedic Clinic Objectives Bone structure and
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationACP Colorado-Evidence Based Management of Osteoporosis
ACP Colorado-Evidence Based Management of Osteoporosis Micol S. Rothman, MD Associate Professor of Medicine and Radiology Clinical Director Metabolic Bone Program University of Colorado School of Medicine
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationPEAK BONE MASS can be defined as the maximal bone
0021-972X/00/$03.00/0 Vol. 85, No. 11 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society CLINICAL REVIEW 117 Hormonal Determinants and Disorders
More informationLa terapia dell osteoporosi nel soggetto talassemico Therapy of Thalassemia Major-Induced Osteoporosis
La terapia dell osteoporosi nel soggetto talassemico Therapy of Thalassemia Major-Induced Osteoporosis Ashraf Soliman, Vincenzo De Sanctis Mohamed A Yassin, Institutes Departments of Pediatric Endocrinology,
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationAn Evidence-based Review of Clinical Trial Data
An Evidence-based Review of Clinical Trial Data Karen K. Miller, MD Massachusetts General Hospital Harvard Medical School Boston, MA 1 Rationale for Investigating Androgen Administration in Women: Data
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationBONE HEALTH Dr. Tia Lillie. Exercise, Physical Activity and Osteoporosis
BONE HEALTH Dr. Tia Lillie Exercise, Physical Activity and Osteoporosis Food for thought... How old would you be if you didn t know how old you were? DEFINITION: Osteoporosis Osteoporosis (OP) is a disease
More informationΑίηια ανδρικής οζηεοπόρωζης - Βιβλιογραθικές πηγές
Αίηια ανδρικής οζηεοπόρωζης - Βιβλιογραθικές πηγές 1. National Osteoporosis Foundation. Clinician s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation,
More informationDISCLOSURES TOPICS" PATHOPHYSIOLOGY of OSTEOPOROSIS: Pathways That Control Bone Remodeling! Why Do Bones Remodel?" Nothing to disclose
PATHOPHYSIOLOGY of OSTEOPOROSIS: Pathways That Control Bone Remodeling Dolores Shoback, MD Professor of Medicine, UCSF Staff Physician SF/VAMC May 19, 2017 DISCLOSURES Nothing to disclose No conflicts
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More information